VIscher appointed managing associates Basile Walder, Elias Mühlemann and Luzius Zumstein to head the firm’s startup desk. The trio succeeds partners Christian Wyss, Damien Conus and Gian-Andrea Caprez, previous heads of the desk.
Tags :Christian Wyss
Vischer advised FimmCyte, a Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, in connection with its research collaboration and option-to-license agreement with Gedeon Richter, a pharmaceutical company specialised in women’s health, with headquarters
Vischer advised Oncobit as the Swiss specialist in precision oncology entered a strategic partnership with ID Solutions, a French company specialising in oncologic diagnostic solutions. The two companies aim at developing a new generation of
Vischer advised Proteomedix, a Swiss biotech subsidiary of Onconetix, on a licensing agreement with Swedish pancreatic cancer diagnostics company Immunovia. The agreement Under the terms of the agreement, Proteomedix will supply Immunovia with master
Vischer advised Medartis, an SIX-listed orthopedic company with headquarters in Basel specialising in head and extremity surgery, on its acquisition of the remaining 53% of Geneva-based KeriMedical. Pursuant to the deal, Medartis becomes the sole owner
Walder Wyss and Vischer are amongst the firms involved in Granite Bio’s Series A and Series B financing round. In particular Vischer advised Forbion and Sanofi Ventures on all legal issues related to their
EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro Ocampo’s laboratory at the University of Lausanne, has raised EUR 10 million from Prima Materia, an investment
